For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
NICE DRAFT RECOMMENDATION ON COST EFFECTIVENESS
Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the National Institute for Health and Clinical Excellence (NICE) in the UK has issued a preliminary opinion that Bronchitol (inhaled dry powder mannitol) could not yet be considered a cost-effective use of NHS resources for the treatment of cystic fibrosis in England and Wales. This opinion is not NICE’s final guidance on Bronchitol and the recommendations may change following consultation and receipt of stakeholder comment.
Bronchitol has been introduced in the United Kingdom at a retail price of £16.55 per day and notification has been received from the UK Department of Health that this price is acceptable.
PRICE IN GERMANY
Pharmaxis today officially published the retail price of Bronchitol in Germany at €35.65 per day. Germany's Federal Joint Committee (G-BA) has a modified procedure for orphan drug assessments such that only products with annual sales in Germany of more than €50 million will be subject to an early benefit assessment from the Institute for Quality and Efficiency in Health Care (IQWiG).
Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) seeking approval for Bronchitol® for the treatment of patients with cystic fibrosis in the United States. The FDA has previously granted Bronchitol Orphan Drug designation for the treatment of patients with cystic fibrosis.
Read full media release - pdf